BCTX BriaCell Therapeutics Corp.
USHealthcareAs of 2026-07-10 16:00
Why BCTX matters now
BriaCell Therapeutics Corp. (BCTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.94 with +8.24% on the session and $7.4M in market capitalization; recent performance reads 1-month -17.38% and YTD -59.21%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-7.2M, and EPS of $-0.99. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -567.2%.
The latest indexable market news headline is "BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.87
P/S
0.00
EV/EBITDA
0.04
DCF Value
$4.19
FCF Yield
-567.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-147.9%
ROA
-113.2%
ROIC
-136.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-7.2M | $-0.99 |
| Q2 2026 | $0.00 | $-7.4M | $-2.62 |
| Q1 2026 | $0.00 | $-11.5M | $-4.35 |
| Q4 2025 | $0.00 | $-11.1M | $-5.87 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
1.64
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.